Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells

Oncology Reports

Volumn 36, Issue 2, 2016, Pages 676-684

  Ma, Jian ^a   Yang, Yan Ru ^a   Chen, Wei ^a   Chen, Mei Hua ^a   Wang, Hao ^a   Wang, Xiao Dan ^a   Sun, Li Li ^a   Wang, Feng Ze ^a   Wang, De Cai ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; CHOP; Fluoxetine; Glioma; Temozolomide

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; CASPASE 3; CHOLECYSTOKININ OCTAPEPTIDE; FLUOXETINE; GADD34 PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2ALPHA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DDIT3 PROTEIN, RAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME ASSAY; FLOW CYTOMETRY; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; GLIOMA; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; RAT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; FLUOXETINE; GLIOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; RATS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR CHOP;

EID: 84976467592     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4860     Document Type: Article

References (35)

1. Goodenberger ML and Jenkins RB: Genetics of adult glioma. Cancer Genet 205: 613-621, 2012.
2. Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol 109: 93-108, 2005.
3. Wang F, Huang Q and Zhou LY: Analysis of the treatment of gliomas with SEC therapy combined with radiochemotherapy. Eur Rev Med Pharmacol Sci 19: 2400-2405, 2015.
4. Quick A, Patel D, Hadziahmetovic M, Chakravarti A and Mehta M: Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 5: 14-27, 2010.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
7. Neyns B, Tosoni A, Hwu WJ and Reardon DA: Dose-dense temozolomide regimens: Antitumor activity, toxicity, and immunomodulatory effects. Cancer 116: 2868-2877, 2010.
8. Hori YS, Hosoda R, Akiyama Y, Sebori R, Wanibuchi M, Mikami T, Sugino T, Suzuki K, Maruyama M, Tsukamoto M, et al: Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. J Neurooncol 122: 11-20, 2015.
9. Zhang Y, Wang SX, Ma JW, Li HY, Ye JC, Xie SM, Du B and Zhong XY: EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. J Neurooncol 121: 41-52, 2015.
10. Sheehan J, Cifarelli CP, Dassoulas K, Olson C, Rainey J and Han S: Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide. J Neurosurg 113: 234-239, 2010.
11. Park EM and Rosenstein DL: Depression in adolescents and young adults with cancer. Dialogues Clin Neurosci 17: 171-180, 2015.
12. Lauer AL: Treatment of anxiety and depression in adolescents and young adults with cancer. J Pediatr Oncol Nurs 32: 278-283, 2015.
13. Perez-Caballero L, Torres-Sanchez S, Bravo L, Mico JA and Berrocoso E: Fluoxetine: A case history of its discovery and preclinical development. Expert Opin Drug Discov 9: 567-578, 2014.
14. Kannen V, Marini T, Turatti A, Carvalho MC, Brandão ML, Jabor VA, Bonato PS, Ferreira FR, Zanette DL, Silva WA Jr, et al: Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats. Toxicol Lett 204: 134-140, 2011.
15. Koh SJ, Kim JM, Kim IK, Kim N, Jung HC, Song IS and Kim JS: Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am J Physiol Gastrointest Liver Physiol 301: G9-G19, 2011.
16. Kannen V, Hintzsche H, Zanette DL, Silva WA Jr, Garcia SB, Waaga-Gasser AM and Stopper H: Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model. PLoS One 7: e50043, 2012.
17. Mun AR, Lee SJ, Kim GB, Kang HS, Kim JS and Kim SJ: Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res 33: 3691-3697, 2013.
18. Lin KL, Chou CT, Cheng JS, Chang HT, Liang WZ, Kuo CC, Chen IL, Tseng LL, Shieh P, Wu RF, et al: Effect of fluoxetine on [Ca2+]i and cell viability in OC2 human oral cancer cells. Chin J Physiol 57: 256-264, 2014.
19. Lee CS, Kim YJ, Jang ER, Kim W and Myung SC: Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin Pharmacol Toxicol 106: 446-453, 2010.
20. Song T, Li H, Tian Z, Xu C, Liu J and Guo Y: Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells. Onco Targets Ther 8: 2199-2208, 2015.
21. Cloonan SM and Williams DC: The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drugresistant Burkitt's lymphoma. Int J Cancer 128: 1712-1723, 2011.
22. Zhou T, Duan J, Wang Y, Chen X, Zhou G, Wang R, Fu L and Xu F: Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol 33: 1299-1306, 2012.
23. Bijnsdorp IV, Giovannetti E and Peters GJ: Analysis of drug interactions. Methods Mol Biol 731: 421-434, 2011.
24. Ma J, Qiu Y, Yang L, Peng L, Xia Z, Hou LN, Fang C, Qi H and Chen HZ: Desipramine induces apoptosis in rat glioma cells via endoplasmic reticulum stress-dependent CHOP pathway. J Neurooncol 101: 41-48, 2011.
25. Bundeff AW and Woodis CB: Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Ann Pharmacother 48: 777-784, 2014.
26. Dharmshaktu P, Tayal V and Kalra BS: Efficacy of antidepressants as analgesics: A review. J Clin Pharmacol 52: 6-17, 2012.
27. Frick LR, Rapanelli M, Arcos ML, Cremaschi GA and Genaro AM: Oral administration of fluoxetine alters the proliferation/apoptosis balance of lymphoma cells and up-regulates T cell immunity in tumor-bearing mice. Eur J Pharmacol 659: 265-272, 2011.
28. Koch GL: The endoplasmic reticulum and calcium storage. BioEssays 12: 527-531, 1990.
29. Klausner RD and Sitia R: Protein degradation in the endoplasmic reticulum. Cell 62: 611-614, 1990.
30. Wu H, Ng BS and Thibault G: Endoplasmic reticulum stress response in yeast and humans. Biosci Rep 34: e00118, 2014.
31. Oyadomari S and Mori M: Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11: 381-389, 2004.
32. Sano R and Reed JC: ER stress-induced cell death mechanisms. Biochim Biophys Acta 1833: 3460-3470, 2013.
33. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26: 186-197, 2007.
34. Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, Wang QJ and Yang Y: Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 285: 40461-40471, 2010.
35. Zou Y, Wang Q and Wang W: MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma. Mol Med Rep 11: 4591-4596, 2015.